康华生物(300841) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 was ¥228,247,551.98, a decrease of 38.33% compared to the same period last year[6] - Net profit attributable to shareholders for Q3 2021 was ¥331,191,245.13, an increase of 105.74% year-on-year[6] - The net profit excluding non-recurring gains and losses for Q3 2021 was ¥99,931,522.95, down 37.74% compared to the same period last year[6] - Basic earnings per share for Q3 2021 were ¥3.6799, reflecting a 105.74% increase year-on-year[6] - The company’s net profit for the first nine months of 2021 was ¥583,360,526.57, a 69.75% increase compared to the same period in 2020[14] - Net profit for the quarter was CNY 583,360,526.57, up from CNY 343,664,826.66, indicating a year-over-year increase of about 69.8%[66] - The company reported a total comprehensive income of CNY 583,360,526.57, reflecting the same amount as the net profit attributable to the parent company[70] Assets and Liabilities - Total assets as of the end of Q3 2021 reached ¥2,635,367,840.90, a 22.71% increase from the end of the previous year[6] - Total assets increased to CNY 2,635,367,840.90 from CNY 2,147,678,235.61, representing a growth of approximately 22.7%[32] - Total liabilities decreased to CNY 159,129,264.40 from CNY 173,243,939.20, a reduction of approximately 8.1%[41] - Total liabilities reached approximately $173.24 million, with non-current liabilities at $2.92 million[86] Shareholder Information - Shareholders' equity attributable to the parent company was ¥2,476,238,576.50, up 25.42% from the end of the previous year[6] - The total number of ordinary shareholders at the end of the reporting period was 21,763[18] - The largest shareholder, Pingtan Yingke Shengdao Venture Capital Partnership, holds 18.82% of the shares, totaling 16,940,220 shares[18] - The company has a total of 16,940,220 shares held by Pingtan Yingke Shengdao, which are subject to lock-up restrictions until June 16, 2023[21] Cash Flow - The company's cash flow from operating activities showed a significant decline, with a net amount of ¥12,111,036.04, down 95.75% year-on-year[6] - The net cash flow from operating activities decreased by 95.75% to ¥12,111,036.04 compared to ¥284,841,410.60 in the same period last year[17] - Cash inflow from operating activities totaled CNY 558,736,126.98, a decrease from CNY 706,833,372.12 in the previous period[73] - Cash outflow from operating activities was CNY 546,625,090.94, compared to CNY 421,991,961.52 in the previous period, indicating increased operational expenses[73] - The company’s total cash inflow from financing activities was CNY -996,550,000.00, indicating a significant outflow related to financing[76] Investments and R&D - The net cash flow from investing activities improved by 38.73%, amounting to -¥255,135,892.16, compared to -¥416,435,639.42 in the previous year[17] - Research and development expenses rose to CNY 45,771,510.81 from CNY 37,367,940.71, reflecting an increase of about 22.5%[66] - Future outlook includes continued investment in R&D and potential market expansion strategies to enhance growth[66] Inventory and Receivables - The company reported an increase in accounts receivable by 75.54% to ¥619,117,355.72 as of September 30, 2021[14] - Inventory increased by 57.20% to ¥78,466,399.41, attributed to expanded production capacity[14] - Accounts receivable increased significantly to ¥619,117,355.72 from ¥352,683,146.05 year-on-year[26] - The company reported a significant increase in prepayments to ¥76,384,675.64 from ¥28,809,934.07 year-on-year[26] Financial Adjustments and Standards - The company adjusted its financial statements in accordance with new leasing standards, impacting the balance sheet[79] - The company has not made any adjustments related to the new leasing standards for prior comparative data[91] - The third quarter report was not audited, indicating a potential area for further scrutiny[91]